Gastric Transit Time
Conditions
Keywords
metoclopramide video capsule endoscopy gastric transit time
Brief summary
Summary: This study investigates the use of oral dissolving metoclopramide during standard video capsule endoscopy. Metoclopramide is a pro -motility agent, that is, this medication helps with movement through the stomach and small bowel. This study will help us determine the effectiveness of oral dissolving metoclopramide on transit time through the stomach and small bowel of the video capsule that is ingested. This study may help with better diagnoses of pathology in the small bowel. Each patient enrolled in the study will either be assigned to a group that only ingests the capsule or the group that receives the oral dissolving metoclopramide plus capsule. Each patient will undergo the same standard procedures and precaution used during standard video capsule endoscopy. The patients that will qualify for the study are patients that are in need of video capsule endoscopy for further imaging of the small bowel. The patients must meet the inclusion criteria provided in the protocol and must not meet any of the exclusion criteria in the protocol. The hypothesis is that the patients that ingest the metoclopramide will have better capsule images and transit time and will allow for enhanced diagnosis of small bowel pathology.
Interventions
DRUGmetoclopramide
1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
Sponsors
Winthrop University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Patients 18 years - 70 years old, male or female, belonging to any race or ethnic origin. 2. Patients necessitating video capsule endoscopy. 3. Patients who are willing and competent to sign an informed consent and to comply with study related visits and procedures.
Exclusion criteria
1. Patients below the age of 18 or greater than 70 years old. 2. Pregnant patients 3. Patients with a documented history of Parkinson's Disease or Parkinsonian Symptoms, Tardive Dyskinesia, history of neuroleptic malignant syndrome, history or seizure disorder. 4. Patients who are currently taking antipsychotic medications including typical and atypical antipsychotics. 5. Patients taking other drugs that may cause extrapyramidal reactions. 6. Patients with a history of cirrhosis or congestive heart failure. 7. Patients with a history of depression. 8. Patients with uncontrolled hypertension. 9. Patients with renal impairment, creatinine clearance \< 40ml/minute. 10. Patients who have massive gastrointestinal hemorrhage, mechanical obstruction, or perforation. 11. Patients with a known history of pheochromocytoma, as this may precipitate hypertensive crisis. 12. Patients with a known sensitivity or intolerance to metoclopramide. 13. Patients who, in the investigator's opinion, are medically unstable, are unable to give informed consent, or whose risks outweigh the benefits of participating in the study. 14. Vulnerable subjects: Prisoners, persons with decisional incapacity, and any person who are directly involved in the study, including their immediate family members, and anybody who may have any conflict of interest.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gastric Transit Time | Day 1 | Time for transit through small intestine. |
Countries
United States
Participant flow
Recruitment details
This study was ended early, only 6 patients were enrolled, 2 to the research arm, 4 to the control arm.
Participants by arm
| Arm | Count |
|---|---|
| Oral Dissolving Metoclopramide Patient's in this arm will receive the oral dissolving metoclopramide along with the capsule during capsule endoscopy.
metoclopramide: 1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule. | 2 |
| Control Group This is the control group that will only ingest the capsule during video capsule endoscopy. | 4 |
| Total | 6 |
Baseline characteristics
| Characteristic | Oral Dissolving Metoclopramide | Control Group | Total |
|---|---|---|---|
| Age, Continuous | 40 years STANDARD_DEVIATION 5 | 40 years STANDARD_DEVIATION 5 | 40 years STANDARD_DEVIATION 5 |
| Region of Enrollment United States | 2 participants | 4 participants | 6 participants |
| Sex: Female, Male Female | 1 Participants | 2 Participants | 3 Participants |
| Sex: Female, Male Male | 1 Participants | 2 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Primary
Gastric Transit Time
Time for transit through small intestine.
Time frame: Day 1
Population: No data were collected from the enrolled participants. Study was terminated prior to collection of data.